ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
19.14
+0.59 (3.18%)
At close: Jul 26, 2024, 4:00 PM
18.63
-0.51 (-2.66%)
After-hours: Jul 26, 2024, 5:57 PM EDT
ACADIA Pharmaceuticals Employees
ACADIA Pharmaceuticals had 598 employees as of December 31, 2023. The number of employees increased by 85 or 16.57% compared to the previous year.
Employees
598
Change (1Y)
85
Growth (1Y)
16.57%
Revenue / Employee
$1,360,880
Profits / Employee
-$2,860
Market Cap
3.16B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 598 | 85 | 16.57% |
Dec 31, 2022 | 513 | -1 | -0.19% |
Dec 31, 2021 | 514 | -87 | -14.48% |
Dec 31, 2020 | 601 | 98 | 19.48% |
Dec 31, 2019 | 503 | 73 | 16.98% |
Dec 31, 2018 | 430 | 5 | 1.18% |
Dec 31, 2017 | 425 | 55 | 14.86% |
Dec 31, 2016 | 370 | 210 | 131.25% |
Dec 31, 2015 | 160 | 63 | 64.95% |
Dec 31, 2014 | 97 | 49 | 102.08% |
Dec 31, 2013 | 48 | 22 | 84.62% |
Dec 31, 2012 | 26 | 2 | 8.33% |
Dec 31, 2011 | 24 | -3 | -11.11% |
Dec 31, 2010 | 27 | 0 | - |
Dec 31, 2009 | 27 | -36 | -57.14% |
Dec 31, 2008 | 63 | -80 | -55.94% |
Dec 31, 2007 | 143 | 5 | 3.62% |
Dec 31, 2006 | 138 | 26 | 23.21% |
Dec 31, 2005 | 112 | 11 | 10.89% |
Dec 31, 2004 | 101 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Amedisys | 19,000 |
ICU Medical | 14,000 |
Azenta | 3,500 |
Oscar Health | 2,400 |
iRhythm Technologies | 2,000 |
HUTCHMED (China) | 1,988 |
ADMA Biologics | 624 |
Amicus Therapeutics | 517 |
ACAD News
- 2 days ago - Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 - Business Wire
- 8 days ago - Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting - Business Wire
- 5 weeks ago - New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings - Business Wire
- 2 months ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome - Business Wire
- 2 months ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - Business Wire